Lung disease in the cystic fibrosis mouse exposed to bacterial pathogens

Nature Genetics
Donald J DavidsonDavid J Porteous

Abstract

Lung disease is the major cause of death in cystic fibrosis (CF), but there is no evidence for overt lung involvement at birth. We show here that the same is true for the gene targeted cftrm1HGU mutant mouse. Furthermore, this CF mouse model demonstrates an impaired capacity to clear Staphylococcus aureus and Burkholderia (Pseudomonas) cepacia, two opportunistic lung pathogens closely associated with lung disease in CF subjects. The cftrm1HGU homozygotes display mucus retention and frank lung disease in response to repeated microbial exposure. Thus, lung disease in the cftrm1HGU mouse develops in response to bacterial infection, establishing a model to dissect the pathogenesis of CF pulmonary disease and providing a clinically relevant end point to assess the efficacy of pharmacologic or genetic interventions.

References

Jan 1, 1976·Archives of Disease in Childhood·D B YeatesN Aspin
Oct 1, 1992·British Medical Bulletin·J R Govan, J W Nelson
Aug 21, 1992·Science·J N SnouwaertB H Koller
Jan 1, 1991·Clinical Microbiology Reviews·P H Gilligan
Feb 1, 1984·The Journal of Pediatrics·A IslesH Levison
Dec 17, 1981·The New England Journal of Medicine·M KnowlesR Boucher
Oct 1, 1993·Human Molecular Genetics·W K O'NealA Bradley
Feb 1, 1994·FEMS Immunology and Medical Microbiology·J W NelsonJ R Govan
May 1, 1993·Nature Genetics·R RatcliffW H Colledge
Aug 1, 1994·Mammalian Genome : Official Journal of the International Mammalian Genome Society·J R DorinD J Porteous
Oct 28, 1993·The New England Journal of Medicine·UNKNOWN Cystic Fibrosis Genotype-Phenotype Consortium

❮ Previous
Next ❯

Citations

Jan 1, 1995·Journal of Inherited Metabolic Disease·J R Dorin
Feb 9, 2011·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·Xiao SuMichael A Matthay
Apr 15, 2010·Applied Microbiology and Biotechnology·Jorge H LeitãoLeonilde M Moreira
Oct 5, 2001·Trends in Genetics : TIG·D J Davidson, M Rolfe
May 23, 2001·Microbes and Infection·C D MohrC A Herfst
Jun 1, 1995·Molecular Medicine Today·P DickinsonD J Porteous
Jun 17, 2011·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Martina WilkeBob J Scholte
Apr 1, 1995·Nature Genetics
Apr 1, 1996·Nature Genetics·X Estivill
Dec 13, 1997·Nature Medicine·D Porteous, D Davidson
Jan 12, 2005·Nature Reviews. Microbiology·Eshwar MahenthiralingamJoanna B Goldberg
Feb 27, 2001·The Pediatric Infectious Disease Journal·M Conese, B M Assael
May 16, 2002·Infection and Immunity·Gillian MorrisonJulia Dorin
May 1, 1998·American Journal of Respiratory and Critical Care Medicine·D GosselinD Radzioch
Oct 1, 1996·American Journal of Respiratory and Critical Care Medicine·S de BentzmannE Puchelle
Nov 8, 2005·American Journal of Respiratory and Critical Care Medicine·Anna M van HeeckerenPamela B Davis
Aug 19, 2007·American Journal of Respiratory and Critical Care Medicine·Michal A OlszewskiGalen B Toews
Apr 17, 2010·American Journal of Respiratory and Critical Care Medicine·Malcolm BrodlieChristopher Ward
Dec 9, 1998·American Journal of Respiratory Cell and Molecular Biology·V L CressmanB H Koller
May 26, 1999·American Journal of Respiratory Cell and Molecular Biology·D W BorthwickJ R Dorin
Aug 5, 2006·American Journal of Respiratory Cell and Molecular Biology·Claudine GuilbaultDanuta Radzioch
Feb 2, 2008·American Journal of Respiratory Cell and Molecular Biology·Tom N HilliardEric W F W Alton
Mar 1, 1996·The Journal of Clinical Investigation·J M Wilson
Mar 31, 2006·BMC Genetics·Nikoletta CharizopoulouBurkhard Tümmler
Dec 16, 2003·Proceedings of the National Academy of Sciences of the United States of America·David R KoehlerJim Hu
May 20, 1998·Proceedings of the National Academy of Sciences of the United States of America·J D LiC Basbaum
Feb 13, 2003·Proceedings of the National Academy of Sciences of the United States of America·Fadie T ColemanGerald B Pier
Mar 9, 2010·Experimental Lung Research·Malcolm BrodlieChristopher Ward
Nov 4, 2000·Expert Opinion on Investigational Drugs·E Alton, C Kitson
Nov 22, 2005·Expert Opinion on Drug Delivery·Stephen Tate, Stuart Elborn
Jan 1, 1995·British Medical Bulletin·W H Colledge, M J Evans
Dec 9, 2008·Pharmacology & Therapeutics·Christopher M Evans, Ja Seok Koo
Mar 3, 2007·Seminars in Pediatric Neurology·Andrea L Gropman, David R Adams
Jul 14, 2007·Cellular Microbiology·Silvia A SousaGerd Döring
Sep 6, 2013·Magnetic Resonance in Medicine : Official Journal of the Society of Magnetic Resonance in Medicine·Matthew S FreemanBastiaan Driehuys
Aug 24, 2013·Pediatric Pulmonology·John K WongUNKNOWN Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF)

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.